KUALA LUMPUR: Duopharma Biotech Bhd
recorded a net profit of RM60.59mil in the six months ended June 30, 2026, as compared to RM45.84mil in the year-ago period, underpinned by a more favourable product mix, the strengthening of the ringgit, which reduced input costs, and continued operational efficiencies.
The pharmaceutical group said in a results filing to Bursa Malaysia, its revenue for the period slipped slightly to RM482.24mil from RM484.52mil in the comparative period due to the normalisation of insulin sales to the public sector following the one-off surge recorded in the first half of FY25.
For the second quarter of the year (2Q), Duopharma's net profit rose to RM29.87mil fom RM20.2mil. Quarterly revenue increased to RM234.36mil from RM221.78mil in the year-ago quarter.
In line with its performance for the period, the board of directors declared an interim dividend of 1.5 sen per share with entitlement date on Sept 4, 2026, and payment date on Sept 21, 2026.
Duopharma said its resilient financial performance in the first half of 2026, supported by its healthy order book, diversified revenue streams and established presence in the public healthcare sector, provides a solid foundation for the remainder of the financial year.
Nevertheless, the group remains mindful of evolving geopolitical developments and global trade uncertainties, which may continue to contribute to volatility in energy prices, foreign exchange movements and Active Pharmaceutical Ingredient (API) costs.
"Supported by its resilient operating fundamentals and the continued execution of its strategic priorities, the group remains cautiously optimistic of delivering a satisfactory performance for the financial year ending Dec 31, 2026, barring any unforeseen circumstances," it said.
Duopharma Biotech group CEO Wan Amir-Jeffery Wan Abdul Majid said in a statement, the resilient financial performance was backed by a healthy order book, diversified revenue streams and strong participation in the public and private healthcare sector.
"To maintain this trajectory, with evolving geopolitical developments and global trade uncertainties in mind, we will continue to focus on operational excellence, prudent cost management and disciplined execution of strategic priorities, while strengthening supply chain resilience through diversified API sourcing, effective inventory management and close collaboration with key suppliers," he said.
